# US 2009/0264779 A1 · Predicting risk of major adverse cardiac events

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0264779 A1
- Document ID: US20090264779A1
- Status: Published application
- Kind: A1
- Application number: 12/425,956
- Filed: 2009-04-17
- Published: 2009-10-22
- Earliest claimed: 2008-04-18
- Assignees: Critical Care Diagnostics, Inc.
- Inventors: James V. Snider; Eugene R. Heyman
- Web page: https://patentgrep.com/patent/US20090264779A1

## CPC

- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6869: {Interleukin}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 2600/158: Expression markers
- G01N 2333/58: Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
- G01N 2333/7155: for interleukins [IL]
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/50: Determining the risk of developing a disease
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.

## Claims

### Claim 1

A method for evaluating the risk of a major adverse cardiac event (MACE) for a subject within one year, the method comprising:
determining a MACE risk score (MACERS) for a subject based upon, at least in part, the ratio of a second level of Growth Stimulation-Expressed Gene 2 (ST2) in the subject at a second time (ST2 T0) to a first level of ST2 in the subject at a first time (ST2 T1), in combination with a weighted logarithm of a level of a natriuretic peptide (NP) in the subject at the second time (NP T1), and
comparing the MACERS to a reference MACERS; wherein the MACERS in comparison with the reference MACERS is indicative of the subject's risk of a MACE within one year.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
obtaining a first level of ST2 in the subject at a first time point, to determine ST2 T0;
obtaining a second level of ST2 in the subject at a second time point, to determine ST2 T1; and
obtaining a level of an natriuretic peptide (NP) in the subject at the second time point, to determine NP T1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the logarithm of NP T1 includes a natural logarithm.

### Claim 4 (depends on 1)

The method of claim 1, wherein the MACERS is determined using the following formula:
MACERS=(ST2T1/ST2T0)+α ln(NPT1),
wherein the coefficient alpha is a weighting factor for the variable it acts on.

### Claim 5 (depends on 4)

The method of claim 4, wherein the coefficient alpha is about 0.33.

### Claim 6 (depends on 1)

The method of claim 1, wherein the NP is brain-type natriuretic peptide (NT-proBNP).

### Claim 7 (depends on 1)

The method of claim 1, wherein the first time point is within 1-7 days of the onset of symptoms.

### Claim 8 (depends on 1)

The method of claim 1, wherein the second time point is 2-14 days after the first time point.

### Claim 9 (depends on 1)

The method of claim 1, wherein the adverse event is selected from the group consisting of recurrence of an initial cardiac event; angina; decompensation of heart failure; admission for cardiovascular disease (CVD); mortality due to CVD; and transplant.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject has been diagnosed with heart failure.

### Claim 11 (depends on 1)

The method of claim 1, wherein the reference MACERS represents a score corresponding to a low risk of an adverse event within one year.

### Claim 12 (depends on 1)

The method of claim 1, wherein the sample comprises serum, blood, plasma, urine, or body tissue.

### Claim 13 (depends on 1)

The method of claim 1, wherein the reference MACERS is about 3.2, and a score that is greater than or equal to the reference score indicates that the subject has an elevated risk of an adverse event within one year, compared to a subject with a score below the reference level.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject has a BMI of 25-29, a BMI of ≧30, or renal insufficiency.

### Claim 15 (depends on 1)

The method of claim 1, wherein a decision to discharge or continue to treat on an inpatient basis is made based on the MACERS.
